StockNews.com began coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research note released on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock. Several other analysts have also recently commented on MRTX. Piper Sandler cut shares of Mirati Therapeutics from an overweight rating to a neutral rating and […]